Novel antigen associated with the neovasculature of tumour metastases
AssigneePhilogen S.P.A.
InventorsJascha-Nikolai Rybak, Christoph Rosli, Alessandra Villa, Giovanni Neri, Dario Neri
Life of this patent
Estimating the term…
Abstract
The invention relates to a binding member that binds the Extra Domain-A (ED-A) isoform of fibronectin for the treatment of tumour metastases.
Claims20
An isolated nucleic acid encoding a VH domain, wherein the VH domain comprises three complementarity determining regions (CDRs) comprising the amino acid sequences of SEQ ID NO:83, SEQ ID NO:4 and SEQ ID NO:5.
An isolated nucleic acid encoding a VL domain, wherein the VL domain comprises three CDRs comprising the amino acid sequences of SEQ ID NO:86, SEQ ID NO:7 and SEQ ID NO:8.
An isolated nucleic acid encoding an antibody, or antigen binding fragment thereof, that binds the Extra Domain-A (ED-A) isoform of fibronectin, wherein the antibody or antigen binding fragment thereof, comprises:
- a set of CDRs, HCDR1, HCDR2 and HCDR3, wherein:
- HCDR1 comprises the amino acid sequence of SEQ ID NO:
- 83,
- HCDR2 comprises the amino acid sequence of SEQ ID NO:
- 4, and
- HCDR3 comprises the amino acid sequence of SEQ ID NO:
- 5;
- and
- further comprises a set of CDRs, LCDR1, LCDR2 and LCDR3, wherein:
- LCDR1 comprises the amino acid sequence of SEQ ID NO:
- 86,
- LCDR2 comprises the amino acid sequence of SEQ ID NO:
- 7, and
- LCDR3 comprises the amino acid sequence of SEQ ID NO:
- 8.
Dependencies are inferred from the claim text.